Resistance Developing after Long-term Ganciclovir Prodrug Treatment in a Preclinical Model of NSCLC

Anticancer Research

Volumn 24, Issue 2 B, 2004, Pages 827-831

  Kurdow, Roland ^a   Schniewind, Bodo ^a   Boehle, Arnd S ^a   Haye, Sieglinde ^a   Boenicke, Lars ^a   Dohrmann, Peter ^a   Kalthoff, Holger ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Gene therapy; Herpes simplex virus thymidine kinase; Lung cancer; Retroviral vector

Indexed keywords

GANCICLOVIR; PRODRUG; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LONG TERM CARE; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SCID MOUSE; TUMOR GROWTH;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GANCICLOVIR; GENE EXPRESSION; GENE THERAPY; HUMANS; IMMUNOBLOTTING; LUNG NEOPLASMS; MICE; MICE, SCID; PRODRUGS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 2442434755     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Elshami AA, Kucharczuk JC, Zhang HB et al: Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther 7: 141-148, 1996.
2. Gao Ding C, An W and Dai J: Retrovirus-mediated herpes simplex virus thymidine kinase gene therapy approach for hepatocellular carcinoma. Cell Res 9: 225-235, 1999.
3. Moolten FL, Wells JM, Heyman RA and Evans RM: Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum Gene Ther 1: 125-134, 1990.
4. Beltinger C, Fulda S, Kammertoens T, Uckert W and Debatin KM: Mitochondrial amplification of death signals determines thymidine kinase/ganciclovir-triggered activation of apoptosis. Cancer Res 60: 3212-3217, 2000.
5. Kianmanesh AR, Perrin H, Panis Y et al: A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther 8: 1807-1814, 1997.
6. Mullen CA, Anderson L, Woods K, Nishino M and Petropoulos D: Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses. Hum Gene Ther 9: 2019-2030, 1998.
7. Vrionis FD, Wu JK, Qi P et al: The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther 4: 577-585, 1997.
8. Andrade-Rozental AF, Rozental R, Hopperstad MG et al: Gap junctions: the "kiss of death" and the "kiss of life". Brain Res Brain Res Rev 32: 308-315, 2000.
9. Shand N, Weber F, Mariani L et al: A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 10: 2325-2335, 1999.
10. Yang L, Hwang R, Chiang Y et al: Mechanisms for ganciclovir resistance in gastrointestinal tumor cells transduced with a retroviral vector containing the herpes simplex virus thymidine kinase gene. Clin Cancer Res 4: 731-741, 1998.
11. Zhang L, Wikenheiser KA and Whitsett JA: Limitations of retrovirus-mediated HSV-tk gene transfer to pulmonary adenocarcinoma cells in vitro and in vivo. Hum Gene Ther 8: 563-574, 1997.
12. Kurdow R, Boehle AS, Haye S et al: Ganciclovir prodrug therapy is effective in a murine xenotransplant model of human lung cancer. Ann Thorac Surg 73: 905-910, 2002.
13. Hinz S, Trauzold A, Boenicke L et al: Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 19: 5477-5486, 2000.
14. Tomayko MM and Reynolds CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24: 148-154, 1989.
15. Smitt PS, Driesse M, Wolbers J, Kros M and Avezaat C: Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther 7: 851-858, 2003.
16. Golumbek PT, Hamzeh FM, Jaffee EM et al: Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J Immunother 12: 224-230, 1992.
17. Graessmann A, Sandberg G, Guhl E and Graessmann M: Methylation of single sites within the herpes simplex virus tk coding region and the simian virus 40 T-antigen intron causes gene inactivation. Mol Cell Biol 14: 2004-2010, 1994.
18. Chou S, Erice A, Jordan MC et al: Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 171: 576-583, 1995.
19. Wolf DG, Smith IL, Lee DJ et al: Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J Clin Invest 95: 257-263, 1995.
20. Agard C, Ligeza C, Dupas B et al: Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis. Cancer Gene Ther 8: 128-136, 2001.
21. Freund CT, Tong XW, Rowley D et al: Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro. Urol Oncol 21: 197-205, 2003.
22. Tong X, Shine DH, Agoulnik I et al: Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents. Anticancer Res 18: 3421-3426, 1998.
23. Park KH, Kim G, Jang SH et al: Gene therapy with GM-CSF, interleukin-4 and herpes simplex virus thymidine kinase shows strong antitumor effect on lung cancer. Anticancer Res 23: 1559-1564, 2003.